{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:28:07Z","timestamp":1775737687693,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2012 N.13534"],"award-info":[{"award-number":["IG 2012 N.13534"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011957","name":"Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.cllc.2019.06.019","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T22:38:11Z","timestamp":1561502291000},"page":"e652-e660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"20","author":[{"given":"Claudia","family":"Proto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Mallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsela","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0526-0835","authenticated-orcid":false,"given":"Monica","family":"Ganzinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Leuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Gabriella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Botta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Trama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.06.019_bib1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC Mesothelioma Staging Project: improving staging of a rare disease through international participation. IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions","volume":"12","author":"Pass","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related diseases","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.cllc.2019.06.019_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/carcin\/bgv097","article-title":"Gene-asbestos interaction in malignant pleural mesothelioma susceptibility","volume":"36","author":"Tunesi","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cllc.2019.06.019_bib4","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2019.06.019_bib5","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0003-4975(99)01038-3","article-title":"Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically","volume":"68","author":"Rusch","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2019.06.019_bib6","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: Proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Mesothelioma","volume":"12","author":"Rusch","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1510\/icvts.2010.255893","article-title":"What is the best way to diagnose and stage malignant pleural mesothelioma?","volume":"2","author":"Zahid","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.cllc.2019.06.019_bib8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"13","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2019.06.019_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","article-title":"Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma","volume":"115","author":"Pass","year":"1998","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2019.06.019_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2214\/AJR.11.7015","article-title":"Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume","volume":"198","author":"Gill","year":"2012","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.cllc.2019.06.019_bib12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/JTO.0b013e3181dd0ef1","article-title":"Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans","volume":"5","author":"Liu","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1148\/radiol.2252011604","article-title":"CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques-initial observations","volume":"225","author":"Prasad","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.cllc.2019.06.019_bib14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2019.06.019_bib15","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00330-008-0918-9","article-title":"Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT","volume":"18","author":"Plathow","year":"2008","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cllc.2019.06.019_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2019.06.019_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.lungcan.2015.08.012","article-title":"Response evaluation in mesothelioma: beyond RECIST","volume":"90","author":"Cheng","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.06.019_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/annonc\/mds535","article-title":"Disease volumes as a marker for patient response in malignant pleural mesothelioma","volume":"24","author":"Labby","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/JTO.0b013e31828354c8","article-title":"Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma","volume":"8","author":"Labby","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejrad.2009.02.002","article-title":"Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma","volume":"74","author":"Ak","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cllc.2019.06.019_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A\u00a0multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2019.06.019_bib22","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib23","doi-asserted-by":"crossref","first-page":"1601428","DOI":"10.1183\/13993003.01428-2016","article-title":"Impact of tumor thickness on survival after radical radiation and surgery in malignant pleural mesothelioma","volume":"49","author":"de Perrot","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2019.06.019_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djx175","article-title":"Quantitative clinical staging for patients with malignant pleural mesothelioma","volume":"110","author":"Gill","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2019.06.019_bib25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American multicenter volumetric CT study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2018.01.001","article-title":"Computed tomography in the evaluation of malignant pleural mesothelioma\u2013association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival","volume":"116","author":"Paajanen","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.06.019_bib27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.06.019_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5301\/tj.5000436","article-title":"Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?","volume":"102","author":"Signorelli","year":"2016","journal-title":"Tumori"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419301706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419301706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:25Z","timestamp":1761505825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419301706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1525730419301706"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.06.019","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}